Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315646652> ?p ?o ?g. }
- W4315646652 endingPage "1045" @default.
- W4315646652 startingPage "1032" @default.
- W4315646652 abstract "Background: Unresectable cholangiocarcinoma prognosis can be extremely variable due to different symptoms and sites of disease involvement at diagnosis and unpredictable chemotherapy response rates. Most patients will usually receive 1st line palliative chemotherapy with platinum compounds and Gemcitabine or Gemcitabine alone. Only a few patients maintain adequate performance status after first-line treatment failure: second-line treatment with FOLFOX or FOLFIRI chemotherapy has been used in this setting with modest overall survival improvement. There is a lack of data concerning whether laboratory findings might help clinicians in identifying those patients with the highest likelihood of benefiting from 2nd line treatment. The aim of this analysis is to assess the prognostic role of a series of easily available laboratory tests in patients with bile duct cancer who received 2nd line chemotherapy. Patients and Methods: Patients with unresectable bile duct cancer treated in 2nd-line setting with platinum-based chemotherapy doublet or FOLFIRI were enrolled. The primary objective of the analysis was to assess overall survival (OS) differences among patients based on the results of lab tests. Serum hemoglobin, neutrophil, lymphocyte, monocyte, platelet absolute count, creatinine, total bilirubin, albumin, LDH, circulating CEA and CA19.9 values were collected at the start of 2nd line treatment. Cut-off values for all lab tests were set by ROC curve analysis. Survival was calculated by the Kaplan–Meier method and differences in survival among stratification factors were assessed by Log-rank test. Cox-proportional-hazard regression was used for multivariate analysis. Level of statistical significance p was set at 0.05 for all tests. Correction for false discovery error rate was performed by Holm’s stepdown procedure. Results: A total of 46 patients were eligible. Median overall survival of the entire cohort was 8.98 months (95%CI: 6.68–13.93) while mean OS was 17.10 months (standard error: 3.16). Using 6.2 months OS landmark as classification variable for ROC curve analysis, only serum hemoglobin (cut-off: >10 g/dL), albumin (cut-off: >3.5 mg/dL), CA19.9 (cut-off: ≤668 UI/mL), monocyte (cut-off: ≤510/mmc) and neutrophil count (cut-off: ≤5140/mmc) were significantly associated with the chosen end-point. Multivariate analysis confirmed an independent statistically significant impact on overall survival only for hemoglobin (Exp(b): 0.12, p = 0.0023) and neutrophil count (Exp(b): 0.30, p = 0.0039). Based on these results, using both hemoglobin and neutrophil count, three prognostic groups were defined: patients with both favorable factors had 12.63 months median OS vs. 6.75 months of patients with only one favorable factor vs. 1.31 months of those with neither. The difference between these three groups of patients was statistically significant (p < 0.0001). Discussion: Second-line palliative chemotherapy can be a potentially useful option for a few patients with unresectable/metastatic bile duct cancer. Even though assessment of patients’ prognosis might be difficult due to the complex behavior of this disease, a series of easily available laboratory tests might be used for these means: serum hemoglobin and neutrophil count we0re able to define subsets of patients with entirely different prognoses. It is hoped that this score will be prospectively validated in a larger group of patients in order to improve treatment decisions in patients with unresectable bile duct cancer candidate to receive palliative 2nd line chemotherapy." @default.
- W4315646652 created "2023-01-12" @default.
- W4315646652 creator A5009428093 @default.
- W4315646652 creator A5015406288 @default.
- W4315646652 creator A5019053015 @default.
- W4315646652 creator A5020384120 @default.
- W4315646652 creator A5067591586 @default.
- W4315646652 creator A5081721442 @default.
- W4315646652 creator A5082393661 @default.
- W4315646652 creator A5086002445 @default.
- W4315646652 date "2023-01-11" @default.
- W4315646652 modified "2023-09-26" @default.
- W4315646652 title "Hemoglobin and Neutrophil Count as Prognostic Factors in Cholangiocarcinoma Patients in 2nd Line Treatment Setting: Results from a Small Monocentric Retrospective Study" @default.
- W4315646652 cites W104974497 @default.
- W4315646652 cites W128003550 @default.
- W4315646652 cites W1579323575 @default.
- W4315646652 cites W1967250547 @default.
- W4315646652 cites W1977332463 @default.
- W4315646652 cites W1980029123 @default.
- W4315646652 cites W1996600303 @default.
- W4315646652 cites W2002157461 @default.
- W4315646652 cites W2004630197 @default.
- W4315646652 cites W2015143684 @default.
- W4315646652 cites W2019426402 @default.
- W4315646652 cites W2030476677 @default.
- W4315646652 cites W2060370948 @default.
- W4315646652 cites W2096092036 @default.
- W4315646652 cites W2115261608 @default.
- W4315646652 cites W2118278569 @default.
- W4315646652 cites W2148237316 @default.
- W4315646652 cites W2157370605 @default.
- W4315646652 cites W2214799754 @default.
- W4315646652 cites W2220762972 @default.
- W4315646652 cites W2223273945 @default.
- W4315646652 cites W2526881395 @default.
- W4315646652 cites W2529550854 @default.
- W4315646652 cites W2745821917 @default.
- W4315646652 cites W2806058593 @default.
- W4315646652 cites W2905261616 @default.
- W4315646652 cites W2908872367 @default.
- W4315646652 cites W2919904274 @default.
- W4315646652 cites W2938760144 @default.
- W4315646652 cites W2948012423 @default.
- W4315646652 cites W2994856410 @default.
- W4315646652 cites W3029026398 @default.
- W4315646652 cites W3121703177 @default.
- W4315646652 cites W3134748096 @default.
- W4315646652 cites W3144916167 @default.
- W4315646652 cites W4207057093 @default.
- W4315646652 doi "https://doi.org/10.3390/curroncol30010079" @default.
- W4315646652 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36661728" @default.
- W4315646652 hasPublicationYear "2023" @default.
- W4315646652 type Work @default.
- W4315646652 citedByCount "0" @default.
- W4315646652 crossrefType "journal-article" @default.
- W4315646652 hasAuthorship W4315646652A5009428093 @default.
- W4315646652 hasAuthorship W4315646652A5015406288 @default.
- W4315646652 hasAuthorship W4315646652A5019053015 @default.
- W4315646652 hasAuthorship W4315646652A5020384120 @default.
- W4315646652 hasAuthorship W4315646652A5067591586 @default.
- W4315646652 hasAuthorship W4315646652A5081721442 @default.
- W4315646652 hasAuthorship W4315646652A5082393661 @default.
- W4315646652 hasAuthorship W4315646652A5086002445 @default.
- W4315646652 hasBestOaLocation W43156466521 @default.
- W4315646652 hasConcept C121608353 @default.
- W4315646652 hasConcept C126322002 @default.
- W4315646652 hasConcept C143998085 @default.
- W4315646652 hasConcept C207103383 @default.
- W4315646652 hasConcept C2776694085 @default.
- W4315646652 hasConcept C2776705615 @default.
- W4315646652 hasConcept C2776907518 @default.
- W4315646652 hasConcept C2777063308 @default.
- W4315646652 hasConcept C2778260052 @default.
- W4315646652 hasConcept C2780258809 @default.
- W4315646652 hasConcept C2780962732 @default.
- W4315646652 hasConcept C44249647 @default.
- W4315646652 hasConcept C50382708 @default.
- W4315646652 hasConcept C526805850 @default.
- W4315646652 hasConcept C71924100 @default.
- W4315646652 hasConcept C74133956 @default.
- W4315646652 hasConcept C90924648 @default.
- W4315646652 hasConceptScore W4315646652C121608353 @default.
- W4315646652 hasConceptScore W4315646652C126322002 @default.
- W4315646652 hasConceptScore W4315646652C143998085 @default.
- W4315646652 hasConceptScore W4315646652C207103383 @default.
- W4315646652 hasConceptScore W4315646652C2776694085 @default.
- W4315646652 hasConceptScore W4315646652C2776705615 @default.
- W4315646652 hasConceptScore W4315646652C2776907518 @default.
- W4315646652 hasConceptScore W4315646652C2777063308 @default.
- W4315646652 hasConceptScore W4315646652C2778260052 @default.
- W4315646652 hasConceptScore W4315646652C2780258809 @default.
- W4315646652 hasConceptScore W4315646652C2780962732 @default.
- W4315646652 hasConceptScore W4315646652C44249647 @default.
- W4315646652 hasConceptScore W4315646652C50382708 @default.
- W4315646652 hasConceptScore W4315646652C526805850 @default.
- W4315646652 hasConceptScore W4315646652C71924100 @default.
- W4315646652 hasConceptScore W4315646652C74133956 @default.
- W4315646652 hasConceptScore W4315646652C90924648 @default.